Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 13, 2015

View Archived Issues

Mechanism of obesity associated with BDNF SNP

BMS starts phase I study of psoriasis candidate BMS-986165

Genentech initiates phase I trial of DSTA-4637S

Aptose Biosciences forms two epigenetic therapeutic collaborations

Sophiris Bio reports results from phase III trial of PRX-302 in BPH

X-Rx forms autotaxin inhibitor collaboration with Gilead Sciences

Eiger acquires license to lymphedema program from Stanford University

CSL launches influenza vaccines business Seqirus

Horizon Pharma partners with ALR to study Rayos delayed-release tablets for SLE

Initial findings from patient treated with Cell Source's Megadose Drug Combination

Aimmune Therapeutics reports results from phase II follow-on study of AR-101

Intracellular S. aureus killed using a phagolysosome-targeted antibody-antibiotic conjugate

Ora-CAC model delivers successful phase III data for Dextenza

Derma Sciences reports results of futility analyses for phase III trials of aclerastide

RetroSense Therapeutics secures funding to support phase I/II trial of RST-001

NFKB1 identified as a biomarker for severe malarial anemia in pediatric patients

FDA approves label expansion for Harvoni

World Diabetes Day: testing the tissue engineering approach

ProMIS Neurosciences licenses target prediction method from University of British Columbia

Clinical and preclinical data presented for Incyte's IDO inhibitor epacadostat

HiQ-0013 identified as promising candidate for cognitive deficits

Vadastuximab talirine from Seattle Genetics obtains FDA orphan drug designation

MFMER reports development of GRK6 inhibitors

Mitsubishi Tanabe Pharma patents KAT II inhibitors

Novartis discloses PI3K inhibitors

TrKA inhibitors described in recent Pfizer patent

Sunshine Lake Pharma and Calitor Sciences present tyrosine kinase inhibitors

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026